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Background: Alzheimer’s disease (AD) differs from other forms of dementia in its relation
to amyloid beta peptide (Aβ42). Using a cell culture model we previously identified annexin
A5, a Ca2+, and phospholipid binding protein, as an AD biomarker. Plasma level of annexin
A5 was significantly higher in AD patients compared to that in a control group. On the
other hand, AD has been identified to share a number of clinical and pathological features
with Dementia with Lewy bodies (DLB). The present study was done to examine whether
or not plasma annexin A5 is a specific marker for AD, when being compared with the levels
of DLB patients. As Apolipoprotein E (ApoE) gene subtype ε4 (ApoE-ε4) has been noticed
as the probable genetic factor for AD, we also examined and compared ApoE genotype in
both AD and DLB.
Methods: Blood samples were obtained from 150 patients with AD (aged 77.6 ± 6.5
years), 50 patients of DLB (79.4± 5.0) and 279 community-dwelling healthy elderly
individuals of comparable age and sex (75.6± 8.1). All AD patients met NINCDS-ADRDA
criteria and all DLB patients were diagnosed as probable DLB according to the latest
consensus diagnostic criteria. Quantification was done using the Chemiluminescent
Enzyme Immunoassay (CLEIA) Technique (SphereLight assay) using the monoclonal
antibodies against annexin A5. DNA genotyping of ApoE was performed by distinguishing
unique combinations of Hha1 fragments of PCR-amplified genomic DNA products.
Results: The plasma level of annexin A5 was significantly higher in AD patients than
in the healthy individuals (control) (P < 0.0001). The plasma annexin A5 level was also
significantly higher in DLB patients than in the control group (P < 0.0001). From the ROC
curves with plasma annexin A5 concentrations, the mean areas under the curve were
0.863 and 0.838 for the AD/control and DLB/control, respectively. The rate of ApoE4 carrier
status and the frequency of the ε4 allele were significantly higher in AD or DLB than in
control and there was no significant difference between AD and DLB.
Conclusions: These results suggest that both annexin A5 and ApoE4 are common
markers for AD and DLB.
Keywords: plasma biomarker, Alzheimer’s disease, dementia with lewy bodies, annexin A5, Ca2+-stress, ROC
curve, ApoE
INTRODUCTION
The augmented number of dementia patients is remarkable in
the aging of society in advanced countries. Alzheimer’s dis-
ease (AD) accounts for more than half of all dementia, and
Dementia with Lewy bodies (DLB) are the second most com-
mon, accounting for approximately 15% of cases at autopsy
(McKeith et al., 2004), both of which are common forms of
neurodegenerative dementia. DLB shares clinical and patholog-
ical features with other dementia subtypes such as AD, vascular
dementia and Parkinson’s disease (PD), which makes it difficult
to distinguish in clinical practice. Also, the lack of valid and
reliable methods for assessing the core clinical symptoms of
both AD and DLB makes its identification even more difficult.
The diagnosis of AD is reliant on the use of National Institute
of Neurological and Communicative Disorders and Stroke-AD
and related Disorders Association (NINCDS-ADRDA) criteria.
The NINCDS-ADRDA criteria have high sensitivity (0.93), but
low specificity (0.23) in the diagnosis of AD among a group of
patients with cortical dementias [AD and frontotemporal demen-
tia (FTD)] (Varma et al., 1999). On the other hand, consensus
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criteria for DLB were developed in 1996 to assist with the ante-
mortem diagnosis (McKeith et al., 2005). Although the criteria
have high specificity (79–100%), the sensitivity is low (20–60%),
so that the diagnosis can be missed in many cases during life
(Litvan et al., 2003). The revised clinical consensus criteria were
published in 2005, which gives greater diagnostic weight to
clinical features suggestive of DLB (McKeith et al., 2005). In
light of the limited sensitivity of current methods of clinical
diagnosis, it is important to establish additional markers that
can improve diagnostic accuracy in combination with clinical
assessment.
Amyloid β peptide (Aβ), which is a proteolytic product of
amyloid precursor protein (APP), accumulates in the brains of
AD patients. Its toxicity is thought to cause neural cell death
(Mattson, 2004). Amyloid-dependent neurotoxicity is known to
perturb Ca2+ homeostasis in neuronal cells (LaFerla, 2002).
Possibly, Aβ impairs membrane Ca2+ pumps and enhances Ca2+
influx through voltage-dependent channels and ionotropic glu-
tamate receptors. Focusing on this mechanism, we identified the
Ca2+-related protein as a potential biomarker for AD using pri-
mary neurons as a cell culture model (Yamaguchi et al., 2010). It
was shown that the level of annexin A5was augmented in both the
brain and blood plasma in an AD-model mouse (Tg2576 trans-
genic mouse), overexpressing mutant human APP (Yamaguchi
et al., 2010). In addition, the plasma level of annexin A5 was
significantly increased in AD patients compared to that in a con-
trol group (p-value of less than 0.0001 in the logistic regression
analysis), suggesting that annexin A5 is a favorable marker for
AD (Yamaguchi et al., 2010). As annexin A5 binds both Ca2+
and lipids, it might have a role to protect against Ca2+-induced
damage. A defensive role against apoptosis by annexin A5 is also
reported, in that annexin A5 plays a role in interacting with and
reducing the toxicity of the amyloidogenic proteins, islet amyloid
polypeptides and α-synuclein inclusion (Bedrood et al., 2009).
Apolipoprotein E (ApoE), which is a major component of
lipoproteins, is comprised of 299 amino acid residues and plays
a role in the metabolism and redistribution of cholesterol. ApoE
mediates the uptake of lipoprotein particles in the brain via the
low-density lipoprotein (LDL), receptor related protein (LRP),
and the very low-density family lipoprotein receptor (VLDL)
(Mahley, 1988; Paolo and Kim, 2011). The three major iso-
forms of ApoE, referred to as ApoE2, E3, and E4, are products
of three alleles (ε2, ε3, ε4) at a single gene locus (Mahley,
1988). Three homozygous phenotypes (Apo-E2/2, E3/3, and
E4/4) and three heterozygous phenotypes (Apo-E2/3, E3/4, and
E2/4) arise from the expression of any two of the three alleles. The
ε4 allele of the ApoE gene was identified as the strongest genetic
risk factor for AD (Bertram and Tanzi, 2008). Neuropathological
studies demonstrated that the frequency of the ApoE gene sub-
type ε4 (ApoE ε4) allele in DLB is similar to AD and that ApoE4
has also been implicated in the development of DLB (Singletona
et al., 2002). We reported that ApoE4 genotypes were similar in
AD and DLB, giving further evidence that the ε4 allele is a risk
factor for both disorders in Japanese subjects (Kobayashi et al.,
2011).
The present study was done to examine whether or not plasma
annexin A5 is a specific marker for AD, in comparison with the
levels of DLB patients. For that purpose, we analyzed plasma level
of DLB patients and compared with those of AD patients and age-
matched community dwelling healthy persons as a control. We
further discuss taking ApoE4 frequencies into consideration.
MATERIALS AND METHODS
HUMAN BLOOD PLASMA
The Sapporo Medical University Ethics Committee approved
human plasma studies on dementia biomarker study in 2007.
Informed written consent was obtained from all subjects. All
healthy volunteers and patients provided written permission. For
patients with impaired cognition we obtained written permission
from their family in accordance with the Declaration of Helsinki.
Blood samples were obtained from 150 patients with AD (aged
77.6 ± 6.5 years), 50 patients of DLB (aged 79.4 ± 5.0 years), and
279 community-dwelling elderly individuals (healthy volunteers)
of comparable age and sex (75.6 ± 8.1 years). All AD patients
met NINCDS-ADRDA criteria (McKhann et al., 1984) and DLB
patients were diagnosed as probable DLB according to the latest
consensus diagnostic criteria (McKeith et al., 2005). The patient’s
clinical symptoms were evaluated using the revised Hasegawa
Dementia scale (HDS-R) (Hasegawa, 1983), Mini-Mental State
Examination (MMSE), and clinical dementia rating (CDR). The
diagnosis of AD was also confirmed in all patients either by brain
magnetic resonance imaging or single photon emission computed
tomography. Blood was drawn with Venoject II vacuum tubes
containing EDTA-Na (final 4.5mM) (Terumo, Tokyo, Japan) and
the plasma fraction was isolated by centrifugation at 2500 g for
15min. This was repeated once to avoid possible cell debris in
blood. Blood was centrifuged within 6 h after sampling. Plasma
fractions were stored at −80◦C until use.
QUANTIFICATION OF PLASMA LEVEL OF ANNEXIN A5 USING
SANDWICH CLEIA (SPHERELIGHT ASSAY)
Plasma annexin A5 was quantified using the Chemiluminescent
Enzyme Immunoassay (CLEIA) Technique (SphereLight assay) as
described (Yamaguchi et al., 2010). Briefly, annexin A5 present
in the specimen was trapped by a monoclonal antibody (mAb)
against annexin A5 (clone No. 23), conjugated to a glass bead and
a horseradish peroxidase (HRP)-labeled mAb against annexin A5
(clone No. 49). Unbound materials were removed by washing.
The chemiluminescent reagent consists of a luminol solution that
includes a phenol-derivative as an enhancer, to which a hydrogen
peroxide solution was added. The HRP in the bound conjugate
catalyzes the oxidation of the luminol derivative, producing light.
The light signals were read by the Olympus SphereLight180 fully
automated system (Olympus Optical Co., Ltd., Tokyo, Japan).
The amount of HRP conjugate bound was directly proportional
to the annexin A5 concentration. The required time and vol-
ume of the specimens were 20min and 40μl, respectively, for the
SphereLight assay. The detection limit proved to be 0.16 ng/ml for
annexin A5 and this system was useful to quantify plasma annexin
A5 within the range of 0.16–20.0 ng/ml. Reproducible data were
obtained by intra-assay and inter-assay (data not shown). Because
annexin A5 is present in blood cells (Masuda et al., 2004), if
a prolonged period of time has passed (longer than 12 h) after
collecting blood until centrifuging, the plasma annexin A5 level
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increases (data not shown) due to physical damage such as tem-
perature change, osmotic pressure change and so on. To avoid
inducible leakage of annexin A5 from blood cells, all the plasma
was separated by centrifugation within 6 h of sampling. The
detection limit proved to be 0.16 ng/ml of annexin A5 as pre-
viously described (Yamaguchi et al., 2010). We also performed
a plasma dilution test and reproducibility studies of intra-assay
and inter-assay, which confirmed the assay method is reliable
(Yamaguchi et al., 2010).
APOLIPOPROTEIN E (ApoE) GENOTYPING
DNA genotyping of ApoE was performed according to the pro-
tocol described by Hixson and Vernier (1990). Briefly, using a
QIAampDNABloodMini Kit (QIAGEN, Tokyo, Japan), genomic
DNA was extracted from the buffy coat after centrifugation of the
blood sample according to the manufacturer’s instructions. The
leukocyte DNA was amplified by PCR using the oligonucleotide
primers, Primer 1 (59-TAAGCTTGGCACGGCTGTCCAAGGA-
39), and Primer 2 (59-ACAGAATTCGCCCCGGCCTGGTACAC-
39) set on common sequence parts of ApoE isoforms. The
PCR products were digested with HhaI (New England Biolabs,
Japan, Inc., Tokyo, Japan) and the resulting digestion frag-
ments were separated by electrophoresis on polyacrylamide gels
(SuperSepTMDNA 15% gel (Wako, Tokyo, Japan)). Each geno-
type of ApoE was distinguished by unique combinations of Hha1
fragment sizes in all homozygotic and heterozygotic combina-
tions (Hixson and Vernier, 1990). After determining the ApoE
genotypes, we investigated the ApoE4 carrier status and the fre-
quency of the ε4 allele in the 279 controls, 150 AD, and 50 DLB
cases.
STATISTICAL ANALYSIS
The mean response of each experimental group was compared
with its simultaneous control by the unpaired Student’s t-test.
Analysis of variance was used to compare the mean responses
of the experimental and control groups. A significant difference
was set at p < 0.05. Logistic regression modeling was employed
to construct receiver operator curves (ROC) by using JMP 9.0.0
(SAS Institute Inc., Cary, NC) to examine the plasma annexin A5
levels in diagnoses of AD and DLB. ROC curve comparisons were
based on the area under the curve (AUC), SE, and the associated
95% confidence interval (CI). We subsequently calculated sensi-
tivity of the variousmodels using the predicted probability of each
subject by logistic regression modeling with specificity of at least
eighty percent. Fisher’s exact tests were used to assess the frequen-
cies of the ε4 allele between groups using JMP 9.0.0 (SAS Institute,
Cary, NC, USA).
RESULTS
Plasma level of annexin A5 was analyzed using CLEIA Technique
(SphereLight assay) as described inMaterials andMethods. In this
study, we measured 150 samples of AD (age 77.6 ± 6.5), 50 sam-
ples of DLB (age 79.4 ± 5.0), and 279 age-matched community
dwelling healthy persons (age 75.6 ± 8.1) as a control.When aver-
age concentrations of plasma annexin A5 are compared among
AD, DLB, and control groups, the values of AD (3.33 ± 1.60) and
DLB (3.02 ± 1.08) were significantly higher than healthy control
FIGURE 1 | Comparison of plasma levels of annexin A5 in AD, DLB
patients, and healthy volunteers (control). For quantitative analysis, we
established a chemiluminescent enzyme immunoassay system with
monoclonal antibodies against human annexin A5 and measured human
plasma annexin A5. Dot blot is shown. Each point represents the plasma
annexin A5 concentration of individual. AD, Alzheimer’s disease; DLB,
dementia with Lewy bodies.
subjects (1.95 ± 0.68) (Figure 1). The probability of both AD
and DLB can be predicted by a logistic regression model with
the plasma level of annexin A5. The ROC analyses revealed good
separation of patients with either AD or DLB from healthy con-
trol subjects (Figure 2). The areas under the curve were 86.3%
(P < 0.0001) and 83.8% (P < 0.0001) for AD and DLB, respec-
tively. That is statistically significant, suggesting that annexin A5
is also a potential biomarker for both AD and DLB. On the other
hand, no significant difference was observed between AD and
DLB (p = 0.36).
Several risk factors for AD have been suggested such as med-
ical history, life style, environment and genes. Of these, ApoE-ε4
has been noticed as one of the genetic factors. We next identified
ApoE gene typing by analyzing the restriction enzyme products of
the PCR-amplified ApoE gene as shown inMaterials andMethods
(Table 1, Figure 3). In the control group, 51 out of 279 subjects
were ApoE4 carriers (18.3%). Three subjects were homozygous
for the ε4 allele (1.1%) and 48 subjects were heterozygous for the
e4 allele (17.2%). The total frequency of the ε4 allele was 9.7%.
In the AD group, 63 out of 150 subjects were ApoE4 carriers
(42.0%). Nine subjects were homozygous for the ε4 allele (6.0%)
and 54 subjects were heterozygous for the ε4 allele (36.0%). The
total frequency of the ε4 allele was 24.0%. In the DLB group,
21 out of 50 subjects were ApoE4 carriers (42.0%). Three sub-
jects were homozygous for the ε4 allele (6.0%) and 18 subjects
were heterozygous for the ε4 allele (36.0%). The total frequency
of the ε4 allele was 24.0%. ApoE4 frequencies were compared
among AD, DLB, and control groups (Fisher’s exact test). ApoE4
carrier status was significantly different between AD and con-
trol groups (p < 0.0001), and between DLB and control (p =
0.0004). Allele frequencies of ApoE ε4 were significantly higher
in AD (p < 0.0001) and DLB (p < 0.0001) than in the control
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FIGURE 2 | Receiver operating characteristic (ROC) curves showing
prediction of either AD or DLB by plasma annexin A5. The probability of
either AD or DLB can be predicted by a logistic regression model with the
plasma level of annexin A5. The areas under the curve are 86.3 and 83.8%
for AD and DLB, respectively. AD, Alzheimer’s disease; DLB, dementia with
Lewy bodies.
Table 1 | Distribution of ApoE4 carrier status and the frequency of
ApoE ε4 allele in the population of AD, DLB, and control groups.
ApoE4 carrier* ApoE ε4 allele**
Positive Negative Positive Negative
C 51 (18.3%) 228 (81.7%) 57 (10.2%) 501 (89.8%)
AD 63 (42.0%) 87 (58.0%) 72 (24.0%) 228 (76%)
DLB 21 (42.0%) 29 (58.0%) 27 (24.0%) 73 (76.0%)
Numbers in parentheses represent the frequencies of ApoE4 carrier or ApoE
ε4 allele. C, control group; AD, Alzheimer’s disease group; DLB, dementia with
Lewy bodies group.
*Significantly different between AD and control groups (p < 0.0001), and
between DLB and control (p = 0.0004).
**Significantly higher in AD (p < 0.0001) and DLB (p < 0.0001) than in the
control group. No significant differences in rates of ApoE4 carrier status and
the frequencies of the ε4 allele between AD and DLB.
group. However, there were no significant differences in rates of
ApoE4 carrier status (p = 0.57) and the frequencies of the ε4
allele (p = 0.32) between AD and DLB. These results also indicate
the similarity of AD and DLB.
DISCUSSION
SIMILARITY OF AD AND DLB
The toxicity of Aβ is thought to cause neural cell death, which
is involved in the pathogenesis AD (Mattson, 2004). Decreased
degradation or dyscatabolism of Aβ, presumably related to aging,
results in both the accumulation of amyloid beta peptide (Aβ42)
in the brain and the decreased concentration of Aβ42 in CSF.
Thus, lowered concentration of CSF Aβ42 has been noted as
a barometer for AD (Andreasen et al., 2001). AD is the most
common neurodegenerative dementia and DLB is the second
most common. DLB shares clinical and pathological features
with AD, which makes it difficult to distinguish in clinical prac-
tice. The CSF levels of Aβ42 are similar between AD and DLB
(Gomez-Tortosa et al., 2003;Mollenhauer et al., 2005a). Amyloid-
dependent neurotoxicity is known to perturb Ca2+ home-
ostasis in neuronal cells (LaFerla, 2002). Possibly, Aβ impairs
membrane Ca2+ pumps and enhances Ca2+ influx through
voltage-dependent channels and ionotropic glutamate receptors.
Focusing on proteins concerning Ca2+ signaling, we identified
annexin A5 which is augmented in Aβ42 dependent manner and
showed it as a potential biomarker for AD (Yamaguchi et al.,
2010). Moreover, the plasma level of annexin A5 was shown to
be elevated in AD (Yamaguchi et al., 2010). In the present study,
plasma level of annexin A5 was shown to be elevated not only in
AD but also in DLB.
Genetic factors are increasingly recognized as major risk fac-
tors for dementia. Evidence from numerous studies has identified
the ApoE gene on chromosome 19 as a major risk factor for AD.
ApoE, which is a major component of lipoproteins, is comprised
of 299 amino acid residues and plays a role in the metabolism
and redistribution of cholesterol (Hatters et al., 2006). Three
major common isoforms, designated ApoE2, ApoE3, and ApoE4.
ApoE colocalizes with extracellular amyloid deposits, resulting in
isoform-specific clearance of Aβ. However, ApoE isoforms differ-
ently interact with Aβ isoform specific effects on Aβ-clearance.
In ApoE4, domain interaction occurs as a result of a putative
salt bridge, leading to tight structural formation. This interac-
tion does not occur to the same extent in ApoE2 and ApoE3
(Dong et al., 1994; Dong and Weisgraber, 1996). ApoE ε4 is asso-
ciated with an increased risk for AD with an earlier age of disease
onset (Kim et al., 2009). On the other hand, findings regarding
ApoE polymorphisms inDLB have so far been inconclusive. It was
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FIGURE 3 | ApoE carrier statuses of AD (A), DLB (B), and healthy
volunteers (control) (C). ApoE carrier statuses are significantly different
between AD and control, and between DLB and control. However, no
significant differences were observed between AD and DLB. ApoE typing
was done using pcr and restriction enzyme digestion using genomic DNA.
AD, Alzheimer’s disease; DLB, dementia with Lewy bodies.
reported that ApoE4 carrier frequency was the highest in AD
among AD, DLB, and control groups, and it was higher in DLB
than in control groups (Carrillo Garcia et al., 2008). Other find-
ings have shown that ApoE4 carrier and allelic frequencies were
comparable for those with AD and DLB [(Kobayashi et al., 2011)
and Table 1].
Our results for annexin A5 and ApoE4 also revealed similar
characteristics for both AD and DLB patients.
DIFFERENCE BETWEEN AD AND DLB
It is apparent that DLB differs from AD in the disease progres-
sion and cure response experienced by patients. Accordingly, early
differentiation between the two forms of dementia is impor-
tant for effective and safe management (Aarsland et al., 2008;
Sinha et al., 2011). CSF levels of tau protein have been shown
to be significantly lower in DLB than in AD, which may help
to differentiate between the two diseases (Mollenhauer et al.,
2005a,b). On the other hand, another study also suggests that
the concentration of phosphorylated tau in CSF, which is highly
correlated with total tau levels, may provide a higher speci-
ficity to differentiate AD and DLB (Vanderstichele et al., 2006).
α-Synuclein is the major constituent of Lewy bodies found
in neurons in DLB. As a consequence of increased accumu-
lation of α-synuclein intraneuronally in DLB, several studies
have attempted its quantification in CSF. α-Synuclein has been
shown to induce disruption of cellular inorganic ion homeosta-
sis such as Ca2+, leading to cell death (Lowe et al., 2004; Danzer
et al., 2007; Ying et al., 2011). Whereas some groups show a
decrease in the total concentration of CSF α-synuclein in DLB
in comparison to other dementias (Mollenhauer et al., 2008;
Kasuga et al., 2010), other groups do not find the significant
difference for DLB (Spies et al., 1998; Noguchi-Shinohara et al.,
2009). Thus, future study on the discrimination of these diseases
is expected.
ABOUT BIOMARKERS
One of the main focuses of public health is prevention of disease.
Different stages in the disease process can be targeted for pre-
ventative action, including prior to development of the disease,
during the asymptomatic stage, and following clinical diagnosis.
Therefore, three stages of prevention can be recognized (Wright
et al., 2009; Weber et al., 2012).
From the CSF proteins identification, andMRI and PET imag-
ing studies, the alteration of both CSF biomarkers (Aβ42 and Tau)
takes place prior to the appearance of brain structural change or
dementia symptoms (Jack et al., 2010). Our in vitro data demon-
strated that annexin A5 is elevated following the stimulation by
Aβ42 (Yamaguchi et al., 2010). Thus, onset of the annexin A5 ele-
vation in dementia occurs at the similar time to the deposition
of Aβ42. Annexin A5 might be expected to be useful in the sec-
ondary and tertiary stages. It is conceivable that the appropriate
stage for utilizing each biomarker candidate is dependent upon
the properties of the biomarker. Therefore, to determine when
each biomarker candidate should be utilized it will be necessary
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to examine the significance of any biological changes that appear
at various stages.
Discrimination between neurodegenerative and non-
neurodegenerative dementia is another expectation for biomark-
ers. Shared clinical symptoms between AD and depression in
elderly have been reported (Starkstein et al., 2005), which might
lead to confusion in medical intervention. Our preliminary data
suggest that plasma annexin A5 levels of the six patients with
depression was comparable with controls (data not shown),
which might implicate annexin A5 as a biomarker for discrim-
inating between neurodegenerative and non-neurodegenerative
diseases.
Biomarkers should be reliable, reproducible, non-invasive,
simple to perform, and inexpensive. To achieve this role both
protein-based and genetic biomarkers have been particularly
investigated. Especially plasma biomarker is beneficial by being
less invasive in comparison with CSF biomarker. Gene typing
is also less invasive since it is available with leukocytes from a
blood sample and genetic biomarkers are of great use. ApoE4 ε4
is widely recognized as a potential biomarker for the risk of AD.
As we demonstrated in this paper, ApoE ε4 is also a risk factor for
DLB, indicating that ApoE ε4 is unable to discriminate between
AD and DLB. No applicable genetic marker for such purpose
has been reported. Detailed molecular mechanism of the onset
of both AD and DLB may be needed to explore genetic factors.
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